论文部分内容阅读
目的探讨KRAS基因突变与大肠癌临床病理特征及预后的关系。方法应用实时荧光定量PCR法检测90例大肠癌患者KRAS基因突变情况,分析大肠癌KRAS基因突变与临床病理特征及预后的意义。结果 90例患者大肠癌标本中,33例患者检测出KRAS基因突变,突变率为36.7%。有淋巴结转移及有远处转移患者KRAS基因突变率分别高于无淋巴结转移及无远处转移患者(P<0.01)。不同性别、年龄、肿块大小、浸润深度、病理组织学类型患者的KRAS基因突变率差异均无统计学意义(P>0.05)。KRAS基因突变型患者3年生存率低于KRAS基因野生型患者(69.7% vs.96.5%)(P<0.01)。结论检测KRAS基因突变对大肠癌的治疗及预后评估具有重要的意义。
Objective To investigate the relationship between KRAS gene mutation and the clinicopathological features and prognosis of colorectal cancer. Methods The mutation of KRAS gene in 90 patients with colorectal cancer was detected by real-time fluorescence quantitative PCR. The mutation, clinicopathological features and prognostic significance of KRAS gene in colorectal cancer were analyzed. Results Among the 90 patients with colorectal cancer, KRAS gene mutation was detected in 33 patients with a mutation rate of 36.7%. The rates of KRAS gene mutation in patients with lymph node metastasis and distant metastasis were higher than those without lymph node metastasis and without distant metastasis (P <0.01). There was no significant difference in the mutation rate of KRAS gene in patients of different gender, age, mass size, depth of invasion and histopathological types (P> 0.05). The 3-year survival rate of KRAS mutant patients was lower than that of KRAS wild-type patients (69.7% vs 96.5%, P <0.01). Conclusion The detection of KRAS gene mutation is of great significance for the treatment and prognosis of colorectal cancer.